Orchid Pharma Limited has released the transcript of its Q4 FY’26 earnings conference call held on May 26, 2026. The call detailed the company’s financial performance for the fourth quarter and the full fiscal year, alongside strategic initiatives. Management highlighted significant advancements in building a differentiated anti-infectives platform, including progress on the Enmetazobactam acquisition, the 7ACA project, and the Exblifep product.
Orchid Pharma FY’26 Earnings Call Recap
Orchid Pharma Limited held its Q4 FY’26 Earnings Conference Call on May 26, 2026, providing an update on its financial results and strategic progress. The company’s management, led by Managing Director Mr. Manish Dhanuka, discussed the financial performance for the fourth quarter and the full fiscal year ended March 31, 2026.
Financial Performance Overview
For Q4 FY’26, standalone revenue from operations was approximately INR238 crores, largely stable year-on-year. EBITDA for the quarter stood at approximately INR42.3 crores. For the full financial year FY’26, standalone revenue was INR811 crores, compared to INR922 crores in FY’25. FY’26 EBITDA was INR101 crores, down from INR155 crores in the previous year. Management noted that industry-wide pricing and volume pressures impacted profitability, but Q4 showed signs of stabilization.
Strategic Initiatives and Growth Drivers
Merger with Dhanuka Laboratories: The merger is anticipated to create a unified anti-infective platform, leading to improved operational efficiencies and an estimated 1% to 2% EBITDA margin expansion. The formal written order is expected shortly after court vacations.
7ACA Project: This project remains on track, with commissioning targeted for the first quarter of calendar year 2027. The process technology is being continuously validated and optimized.
Exblifep: The product is in the early stages of commercialization in India and Europe, showing encouraging preliminary orders. Discussions are ongoing for commercial opportunities in the United States, Russia, Latin America, and Southeast Asia.
Cefiderocol and AMS: The Cefiderocol facility is on track for commissioning by the end of the calendar year. Product launch is expected during Q2 or Q3 of calendar year 2027. The AMS platform, currently an EBITDA drag of approximately INR8 crores annually, is considered strategically important for positioning Orchid in responsible anti-infective healthcare solutions.
U.S. Market Strategy: Orchid aims to leverage its U.S. FDA-approved sterile Cephalosporin facility by investing further in fill, finish, and formulation capabilities. The objective is to address regulated sterile formulation opportunities in the U.S. market, with plans to launch approximately five to six large sterile products targeting a significant portion of the U.S. Cephalosporin market, estimated at $1.2 billion.
New Product Development: Products under development include Ceftaroline, Ceftazidime-Avibactam, Ceftolozane, Cefepime, Ceftaroline, and Ceftriaxone. These are expected to contribute to Orchid’s top and bottom lines over the next five years.
Market and Pricing Trends
Management acknowledged challenges in antibiotic sales, particularly regarding formulary inclusion and government tenders in Europe. However, they are observing positive feedback on key products and expect sales to grow as market access expands. The lifetime sales potential for Enmetazobactam is estimated between $1 billion to $2 billion.
The base business is expected to grow between 10% to 15% in FY’27. Pricing for 7ACA is currently around $61, with a long-term average of approximately $60, showing stability.
Dhanuka Integration
For Dhanuka, revenue for FY’26 was approximately INR450 crores. EBITDA PAT is under evaluation. The integration is expected to yield efficiency improvements, contributing to an incremental EBITDA for Orchid.
Operational Updates
The company is re-engineering existing plants for downstream processing with minimal investment, aiming for a high asset turn. For the 7ACA project, initial downstream product sales are expected internally, with third-party sales following. The Shionogi’s project plant commissioning is slated for December ’26.
Source: BSE
